Enter assignee name

EPO Patents = 2

Forward Citations = 17

Loading Chart...

4 inventors (with patents filed for the assignee):

Fredric Cohen (3 out of 12 patents)

Per Marin (3 out of 5 patents)

Michel Afargan (2 out of 5 patents)

4. Fred Cohen (1 out of 1 patent)

5. Michael Afargan (0 patent)

9 patents: Sort by Forward Citations

1. 12201632 - Levoketoconazole for treatment of congenital adrenal hyperplasia and primary aldosteronism (2025-01-21),

2. 11903940 - Methods of treating disease with levoketoconazole (2024-02-20),

3. 11478471 - Methods and compositions for treating diabetes, metabolic syndrome and other conditions (2022-10-25),

4. 11278547 - Methods of treating disease with levoketoconazole (2022-03-22),

5. 11020393 - Methods of treating disease with levoketoconazole (2021-06-01),

6. 10987402 - Pharmaceutical compositions of water soluble peptides with poor solubility in isotonic conditions and methods for their use (2021-04-27),

7. 10835530 - Methods and compositions for treating diabetes, metabolic syndrome and other conditions (2020-11-17),

8. 10517868 - Methods and compositions for treating diabetes, metabolic syndrome and other conditions (2019-12-31),

9. 10398751 - Pharmaceutical compositions of water soluble peptides with poor solubility in isotonic conditions and methods for their use (2019-09-03),

Strongbridge Dublin Limited is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company leverages its expertise in rare diseases and orphan drugs to bring innovative treatments to patients in need. With a strong pipeline of product candidates and a commitment to patient-centric care, Strongbridge Dublin Limited is dedicated to making a difference in the lives of those affected by rare diseases.

Profile summary based on public USPTO records.